License, Collaboration and Service Agreements - Additional Information (Detail) $ / shares in Units, $ in Thousands, £ in Millions			1 Months Ended							3 Months Ended				12 Months Ended
	Sep. 21, 2022 USD ($) $ / shares shares	Jan. 15, 2021 USD ($)	Jun. 30, 2021 USD ($)	Feb. 28, 2021 USD ($) shares	Nov. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2016 GBP (£)	May 31, 2016 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($)	Nov. 07, 2022 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred Revenue, Current														$ 10,369	$ 1,857
Revenue recognized														48,579	3,070
Common stock issued, aggregate fair value														14,234	7,831
Remaining Transaction Price Allocated To Performance Obligations														12,500
Milestone payment														225,000
Pfizer Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Issuance of common stock and preferred stock net of offering costs, shares | shares				2,362,348
Common stock issued, aggregate fair value				$ 27,500
GSK SPA [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transaction price allocated to the performance obligations														64,700
Initial Payments Amount to Perform the Obligations														66,000
Discount on Performance of Obligations														1,300
Issuance of common stock and preferred stock net of offering costs, shares | shares	7,450,000
Common stock issued, aggregate fair value	$ 10,300
License and Know-How Transfer [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance Obligation Allocated Transaction Price														1,400
License and Know-How Transfer [Member] | GSK SPA [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transaction price allocated to the performance obligations														64,700
Performance Obligation Allocated Transaction Price														45,700
Research And Development Services Related To Upcoming Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance Obligation Allocated Transaction Price														11,100
Research And Development Services Related To Upcoming Milestones [Member] | GSK SPA [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance Obligation Allocated Transaction Price														19,000
Cantab Related Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payment upon achievement of specified commercial milestone								£ 5.0						6,000
License agreement research and development expense related to achievement of regulatory milestones														$ 0
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones							$ 5,800
Vertex License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract termination period														10 years
Nonrefundable upfront payments									$ 500
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones									$ 80,200
License agreement payment of research and development expense related to achievement of regulatory milestones														$ 0	0
Contract termination period if no material development or commercialization occurs														1 year
Meiji License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Nonrefundable upfront payments						$ 600
Sublicense fee payable to counter party														$ 7,500
Sublicence Fee Paid														6,600
Potential milestone payments upon achievement of specified condition						$ 1,000
License agreement fixed assets related payments													$ 1,600
Potential milestone payments upon completion and delivery of results of a clinical study														1,000
Future milestone payments														$ 1,000
Everest License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Period of option granted on an agreement														12 months
Upfront payment received												$ 3,000
Potential milestone payments upon completion and delivery of results of a clinical study											$ 2,000
Revenue recognized														$ 700	1,300
Milestone payment														34,000
Everest License Agreement [Member] | SPR206 [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment received			$ 800									2,000
Potential milestone payments upon completion and delivery of results of a clinical study		$ 1,500	$ 700
milestones payment received		$ 2,000
Everest License Agreement [Member] | SPR 741 [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment received												$ 1,000
Everest License Agreement [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Agreement termination period upon written notice		180 days
Everest License Agreement [Member] | Maximum [Member] | SPR206 [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Receivable amount upon achievement of certain milestone		$ 38,000												59,500
Everest License Agreement [Member] | Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Agreement termination period upon written notice		90 days
Pfizer License and Share Purchase Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Receivable amount upon achievement of certain milestone										$ 900
milestones payment received										5,000
Deferred Revenue, Current														13,900
Revenue recognized														$ 1,800
Issuance of common stock and preferred stock net of offering costs, shares | shares														2,362,348
Common stock issued, aggregate fair value														$ 27,500
Associated premium as a freestanding equity-linked instrument under ASC 815														12,500
Performance Obligation Allocated Transaction Price										5,000
Pfizer License and Share Purchase Agreements [Member] | SPR206 [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment received														$ 0
Issuance of common stock and preferred stock net of offering costs, shares | shares														2,362,348
Share price | $ / shares														$ 16.93
Proceeds from sale of common stock to related party														$ 40,000
Receivable amount upon achievement of certain milestone														80,000
Pfizer License and Share Purchase Agreements [Member] | Research And Development Services Related To Upcoming Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance Obligation Allocated Transaction Price										$ 4,100
Gates MRI [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Reduction to research and development expense															$ 1,500
Savior Service Agreement [Member] | Prepaid Expenses and Other Current Assets [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-refundable supervision fee related to commercial manufacturing facility					$ 2,000
Savior Service Agreement [Member] | Long-term Asset [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Service agreement additional payment related to facility build out costs														5,300
GSK License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred Revenue, Current														18,600
Revenue recognized														46,100
Issuance of common stock and preferred stock net of offering costs, shares | shares	7,450,000
Share price | $ / shares	$ 1.20805
Common stock issued, aggregate fair value	$ 1,300
GSK License Agreement [Member] | Glaxo Smith Kline [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment																$ 66,000
Change in subsequent payments																50.00%
GSK License Agreement [Member] | License and Know-How Transfer [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized														45,700
GSK License Agreement [Member] | Research And Development Services Related To Upcoming Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance Obligation Allocated Transaction Price														$ 400